We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+1.17%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$47.1B
AUM Growth
-$899M
(-1.9%)
Cap. Flow
-$982M
Cap. Flow
% of AUM
-2.08%
Top 10 Holdings %
Top 10 Hldgs %
35.43%
Holding
967
New
122
Increased
219
Reduced
464
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$250M |
| 2 |
Starbucks
SBUX
|
+$152M |
| 3 |
CERN
Cerner Corp
CERN
|
+$122M |
| 4 |
Colgate-Palmolive
CL
|
+$87.1M |
| 5 |
Procter & Gamble
PG
|
+$77.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$456M |
| 2 |
Cisco
CSCO
|
+$392M |
| 3 |
Analog Devices
ADI
|
+$151M |
| 4 |
United Parcel Service
UPS
|
+$148M |
| 5 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$89.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.05% |
| 2 | Consumer Discretionary | 15.92% |
| 3 | Financials | 12.69% |
| 4 | Healthcare | 12.47% |
| 5 | Communication Services | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LSXMK
301
DELISTED
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
| $14.8M | 0.03% |
476,862
-9,708
| -2% | -$309K |
|
302
Delta Air Lines
DAL
$60.1B
| $14.6M | 0.03% |
266,856
-16,588
| -6% | -$915K |
|
|
HCOM
303
DELISTED
Hawaiian Telcom Holdco, Inc
HCOM
| $14.6M | 0.03% |
546,273
| – | – |
|
|
AERI
304
DELISTED
Aerie Pharmaceuticals
AERI
| $14.5M | 0.03% |
267,672
-9,058
| -3% | -$507K |
|
305
PRA Group
PRAA
$755M
| $14.5M | 0.03% |
381,970
-17,008
| -4% | -$620K |
|
|
RDS.A
306
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $14.5M | 0.03% |
226,603
-31,808
| -12% | -$2.1M |
|
|
AIMT
307
DELISTED
Aimmune Therapeutics
AIMT
| $14.4M | 0.03% |
+453,320
| New | +$16M |
|
308
CoStar Group
CSGP
$12.3B
| $14.3M | 0.03% |
394,590
-7,030
| -2% | -$242K |
|
|
AVNS
309
DELISTED
Avanos Medical
AVNS
| $14.3M | 0.03% |
310,328
+2,646
| +0.9% | +$126K |
|
|
GBT
310
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $14.3M | 0.03% |
295,982
-65,112
| -18% | -$3.63M |
|
311
NorthWestern Energy
NWE
$4.43B
| $14.2M | 0.03% |
263,595
-7,884
| -3% | -$417K |
|
312
Marvell Technology
MRVL
$196B
| $14.2M | 0.03% |
675,244
-130,786
| -16% | -$2.99M |
|
313
Crocs
CROX
$6.55B
| $14.1M | 0.03% |
+868,254
| New | +$12M |
|
|
CVSA
314
Covista Inc
CVSA
$4.8B
| $14M | 0.03% |
295,096
-4,318
| -1% | -$202K |
|
315
Donnelley Financial Solutions
DFIN
$1.16B
| $13.9M | 0.03% |
811,338
-76,264
| -9% | -$1.49M |
|
|
RTN
316
DELISTED
Raytheon Company
RTN
| $13.9M | 0.03% |
64,272
-5,075
| -7% | -$1.05M |
|
317
QuidelOrtho
QDEL
$838M
| $13.7M | 0.03% |
263,801
+2,519
| +1% | +$117K |
|
318
Astronics
ATRO
$3.84B
| $13.6M | 0.03% |
504,834
+50,201
| +11% | +$1.5M |
|
319
Columbus McKinnon
CMCO
$584M
| $13.6M | 0.03% |
380,169
+12,682
| +3% | +$486K |
|
320
Biogen
BIIB
$30.7B
| $13.6M | 0.03% |
49,580
-644
| -1% | -$200K |
|
|
VCRA
321
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $13.5M | 0.03% |
+575,460
| New | +$15.4M |
|
322
First American
FAF
$7.58B
| $13.4M | 0.03% |
229,188
-5,803
| -2% | -$340K |
|
323
argenx
ARGX
$54.1B
| $13.4M | 0.03% |
+166,245
| New | +$12.6M |
|
324
Park Hotels & Resorts
PK
$2.97B
| $13.3M | 0.03% |
492,711
-10,063
| -2% | -$277K |
|
325
Synopsys
SNPS
$79.7B
| $13.3M | 0.03% |
159,401
-30,739
| -16% | -$2.7M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q1 2018 Portfolio in Review
As of Q1 2018, Loomis, Sayles & Company held 967 positions worth $47.1B, down 1.9% from $48B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Loomis, Sayles & Company's Q1 2018 filing shows 122 new, 219 increased, 464 reduced and 97 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 870,638 shares worth $70.6M. The largest sale was Amazon, an estimated $456M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q1 2018 buy was BioMarin Pharmaceuticals: 870,638 shares worth $70.6M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q1 2018, an estimated $250M increase.
- Loomis, Sayles & Company's biggest Q1 2018 reduction was Amazon, cutting an estimated $456M.
- Loomis, Sayles & Company fully exited Analog Devices in Q1 2018, selling an estimated $151M.
- Loomis, Sayles & Company's ten largest holdings make up 35% of its $47.1B portfolio in Q1 2018.
- Loomis, Sayles & Company opened 122 new positions and closed 97 in Q1 2018.
- Loomis, Sayles & Company's portfolio value fell 1.9% quarter-over-quarter to $47.1B.
Based on Loomis, Sayles & Company's 13F filing for Q1 2018, filed 11 May 2018.